Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Assets (2016 - 2025)

Historic Return on Assets for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to 1.92%.

  • Karyopharm Therapeutics' Return on Assets fell 14800.0% to 1.92% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.92%, marking a year-over-year decrease of 14800.0%. This contributed to the annual value of 1.44% for FY2025, which is 10600.0% down from last year.
  • Karyopharm Therapeutics' Return on Assets amounted to 1.92% in Q4 2025, which was down 14800.0% from 1.24% recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Return on Assets ranged from a high of 0.36% in Q1 2022 and a low of 1.92% during Q4 2025
  • Moreover, its 5-year median value for Return on Assets was 0.48% (2023), whereas its average is 0.64%.
  • Per our database at Business Quant, Karyopharm Therapeutics' Return on Assets skyrocketed by 4000bps in 2022 and then plummeted by -14800bps in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Return on Assets stood at 0.44% in 2021, then fell by -27bps to 0.56% in 2022, then grew by 0bps to 0.56% in 2023, then increased by 23bps to 0.43% in 2024, then crashed by -343bps to 1.92% in 2025.
  • Its Return on Assets was 1.92% in Q4 2025, compared to 1.24% in Q3 2025 and 1.06% in Q2 2025.